Product Description
Ropivacaine is a long-acting amide local anaesthetic agent and first produced as a pure enantiomer. It produces effects similar to other local anaesthetics via reversible inhibition of sodium ion influx in nerve fibres. Ropivacaine is less lipophilic than bupivacaine and is less likely to penetrate large myelinated motor fibres, resulting in a relatively reduced motor blockade.
Mechanisms of Action: CYP2D6 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Czech Republic, Denmark, France, Germany, Italy, Mexico, Poland, United States, Unknown Location
Active Clinical Trial Count: 22
Highest Development Phases
Phase 3: Bunion|Osteoarthritis, Knee|Pain, Postoperative|Total Knee Arthroplasty
Phase 2: Anesthesia Related|Other|Pain Unspecified|Tinea
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TLC590A2006 | P2 |
Recruiting |
Pain, Postoperative |
2026-07-01 |
|
| TLC590A2003 | P3 |
Not yet recruiting |
Pain, Postoperative |
2025-12-01 |
95% |
| SIFICB | P2 |
Unknown Status |
Tinea |
2025-02-01 |
|
| CPL-01-302 | P3 |
Recruiting |
Pain, Postoperative|Bunion |
2024-10-31 |